09:52 AM EST - BioSyent Inc. : announced that its subsidiary BioSyent Pharma Inc. has signed an exclusive Canadian Licence and Distribution Agreement with its third European partner for a women's health product that has prior approval from Health Canada. BioSyent Inc.
shares V.RX are trading down $0.08 at $2.34.
